Parkinsonism & Related Disorders

Papers
(The median citation count of Parkinsonism & Related Disorders is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Malignant Neuroleptic Syndrome in a Patient with Huntington's Disease128
Error-based biofeedback for gait training in Parkinson's disease91
APOE carrier status and cognitive outcomes after STN-DBS surgery for Parkinson’s disease.77
Dual Phase 18F-FP-CIT PET in presynaptic and trans-synaptic nigrostriatal dysfunction in Multiple System Atrophy77
A case of probable Progressive Supranuclear Palsy Frontal type (PSP-F) presenting as psychosis76
Leveraging Telehealth and Wearables for Parkinson’s Disease: Innovative Approaches to Enhance Personalized Care75
Effect of ND0612 Continuous Infusion on Motor Performance and Experiences of Daily Living in Patients With Parkinson’s Disease65
Neurocognition, Cerebellar Functions and Psychiatric Features in Spinocerebellar Ataxia Type 3464
FindPD.DaT: Development of a Novel Artificial Intelligence-driven Tool for Diagnosis of Parkinson’s Disease using Dopamine Transporter Scans61
Effects of an intensive, multidisciplinary rehabilitative treatment in an outpatient setting on clinical outcomes in Parkinson’s Disease: preliminary results.47
β-Caryophyllene decreases neuroinflammation and exerts neuroprotection of dopaminergic neurons in a model of hemiparkinsonism through inhibition of the NLRP3 inflammasome41
Perioperative quantification of MDS-UPDRS-III tremor measurements in patients with Parkinson’s Disease using accelerometry41
Association between serum lipid levels and dopamine loss in idiopathic rapid eye movement sleep behavior disorder40
Treatment of refractory post-hypoxic myoclonus and focal epilepsy with subthalamic nuclei deep brain stimulation37
Asymmetric Parkinsonism and Ataxia with autonomic dysfunction and RBD36
Diet quality and prodromal Parkinson's disease probability in isolated REM sleep behavior disorder35
Evaluation of mild cognitive impairment in older patients with essential tremor35
A useful cognitive motor dual task paradigm in prodromal and manifest Huntington’s disease35
Diagnosis of vascular parkinsonism: A new tool for gait hypokinesia occurring in older persons35
Symptom onset lateralization and bilaterality in Parkinson's disease: Clinical implications of motor and non-motor profiles33
Fear among patients with Parkinson's disease and repeated falls: Analysis of skin conductance responses during simulated accidents33
Leigh-like syndrome as a presentation of biallelic variants in DNAJC30 gene with predominant putamen degeneration and limb dystonia32
Hemiatrophy-hemiparkinsonism and Poland syndrome: A causative or coincidental association?32
White matter connectivity networks predict early dementia conversion in Parkinson’s disease30
A novel summary index derived from Kinect to evaluate the severity of postural abnormalities in patients with Parkinson’s Disease30
Critical Appraisal of Economic Evaluation of Biomarkers Used for Screening of Dementia30
Apomorphine sublingual film for “OFF” episodes in Parkinson’s disease: analysis of baseline factors30
Association of Baseline Serum Urate Levels with Longitudinal General Cognition in Non-Demented Parkinson's Disease29
Examination of cognitive function in Parkinson's disease patients with chronic kidney disease29
Early onset hemichorea-parkinsonism with POLG mutation without external ophthalmoplegia responsive to pallidal DBS29
Chorea-Acanthocytosis: A Case Report27
Association and Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson’s Disease–related Cognitive Impairment26
Targeting sedentary behavior decreases depressive symptoms and improves sleep in people with Parkinson’s Disease26
“Pop-up” studies: Observational studies in Huntington disease conducted at annual family convention26
Role of linagliptin, a dipeptidyl peptidase-4 inhibitor against oxidative stress and neuronal damage in experimental diabetic aging brain of female rats of different age groups.26
Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson's disease25
Is rapid eye movement sleep behavior disorder a marker of Parkinson's disease severity?25
Fibrinogen exacerbates GCase ubiquitination via ATF5-induced TRIP12 activation in Parkinson's Disease25
Digital devices and wearable technology for quantification of freezing of gait in adolescents with pediatric movement disorders attending school25
Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?25
Mitochondrial and autophagic dysfunctions of skin fibroblasts derived from pantothenate kinase-associated neurodegeneration patients carrying PANK2 mutations and the rescuing effects of allantoin25
Relation between Clinical and Electrophysiological Correlates of Peripheral Polyneuropathy and Oral Levodopa Treatment in People with Parkinson’s Disease25
Psychometric analysis of the short form UCLA Loneliness Scale (ULS-8) in people with Parkinson's disease25
Integrity of Dopaminergic Terminals in the Caudate Nucleus Modulates Rest Tremor in Parkinson’s Disease25
Cerebello-thalamofrontal dysconnectivity in paroxysmal kinesigenic dyskinesia: A resting-state fMRI study24
The effects of stretching in Parkinson's disease: A systematic review of randomized controlled trials24
Early-onset Parkinson's disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: Results from the global burden of disease study 202123
Assessment of SLC25A46 variants in idiopathic Parkinson's disease23
Associations of cerebrospinal fluid monoamine metabolites with striatal dopamine transporter binding and 123I-meta-iodobenzylguanidine cardiac scintigraphy in Parkinson's disease: Multivariate analyse23
Magnetic resonance spectroscopy reveals evidence of brain oxidative stress in Tourette syndrome23
Understanding microlesion and cognitive interactions in STN-DBS: A clinical perspective23
Establishing a framework for quality of inpatient care for Parkinson's disease: A study on inpatient medication administration23
Prevalence and clinical impact of alpha-synuclein pathology in idiopathic normal pressure hydrocephalus: Insights from RT-QuIC assay23
Longitudinal brain changes in Parkinson's disease with severe olfactory deficit23
Objective sleep enhancement in Parkinson's disease: A sham-controlled trial of low-frequency repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex22
Impaired sleep microarchitecture is associated with locus coeruleus degeneration in Parkinson’s disease22
The Elevated Risk of Dementia in Parkinson's Disease Patients Associated with Metabolic Syndrome22
Plasma microRNA predict cognitive decline in Parkinson's disease22
Machine Learning Analysis of the Interaction Between miR-155 and LRRK2 Gene Variants in Parkinson's Disease Progression22
Retinal microvascular impairment in Parkinson's disease with cognitive dysfunction22
Hemiballistic hemi-myoclonus in Subacute Sclerosing Pan encephalitis – A novel observation22
Study of 17β estradiol with neuropeptide and amyloid beta fragment on neuronal and biochemical functions in naturally menopausal aging rats22
Establishing exercise habits in patients with Parkinson's disease through an exercise group model21
Clinical Evaluation of Parkinson's Disease Patients Admitted to the Movement Disorders Outpatient Clinic of Istanbul Taksim Training and Research Hospital, Turkey, 202321
Association between global cognitive function and autonomic dysfunction in patients with de novo Parkinson’s disease21
Unveiling the Complexity of Parkinson's Disease: Exploring Subtypes and Tracing its Five-Stage Natural Course21
Somnolence-Related Events Over Time During Valbenazine Treatment for Chorea Associated with Huntington’s Disease21
Huntington Disease – Update on Recent Advances and a Look Toward the Future21
A de novo GRIA3 variant with complex hyperkinetic movement disorder in a girl with developmental delay and self-limited epilepsy20
The characteristic and prognostic role of blood inflammatory markers in patients with Huntington's disease from China20
Commentary on “The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials”20
Atypical Presentation of Autosomal Recessive Cerebellar Ataxia Type I Mimicking Amyotrophic Lateral Sclerosis20
The role of neurotrophic factors in development Parkinson's disease dementia20
Carrier Mediated Delivery System Bearing Dopamine for Effective Management of Parkinsonism20
Diverse paths of phenotypic evolution in functional movement disorders: A longitudinal perspective20
Hereditary Spastic Paraparesis with SPG6 mutation: First case report from Malaysia20
Parkinson’s Disease with Hyposmia and Dysautonomia: Does It Represent a Distinct Subtype?20
Efficacy of Once-Daily Valbenazine in Adults with Chorea Associated with Huntington’s Disease: Effect Size Over Time20
From writer's cramp to blepharoclonus: An atypical journey with a novel KMT2B variant19
Functional movement disorders in dopa-responsive dystonia19
Impact of inpatient mobility on outcomes in Parkinson's disease19
Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes19
Deep learning-based MRI segmentation for substantia nigra in Parkinson's disease with cognitive impairment19
Dentate calcifications with palatal tremor and facial myorhythmia in adult-onset Cerebral X-linked Adrenoleukodystrophy19
Sex differences for cognitive decline in progressive supranuclear palsy19
Expert commentary: Teaching points from A young patient with spastic paraparesis and ataxia due to P102L GSS19
The BEACON Study: LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease18
Colony-Stimulating Factor-1 Receptor-Related Disorders in the Hispanic Population: A Report of six Families18
Effect of Safinamide on Non-motor symptoms and QoL According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose18
Protective Lifestyle Risk Factors Against Parkinson’s Disease In Sub-Saharan Africa: A Review On Current Evidence18
A young man with progressive dysarthria, generalized slowness and memory loss18
Dopaminergic dysfunctions instigated by Nano-formulation of Neonicotinoid pesticides in mice18
Cystatin C as a Biomarker for the Development of Parkinson disease in Patients with Chronic Kidney Disease18
Editorial Board17
Expanding the phenotypic and genotypic spectrum of DYT-TUBB4A with seven patients from India17
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks17
Association of bilateral oophorectomy with incidence of Parkinson's disease: A systematic review and meta-analysis17
A late-onset neurological disorder: Is progression inevitable? Expert Commentary17
Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy17
Brittle dyskinesias after bilateral STN DBS: dissociation of microlesioning effect on tremor versus on dyskinesias17
Machine Learning-based World Health Organization Disability Assessment Schedule for persons with Parkinson's disease17
On demand inhaled levodopa in Parkinson´s disease (pd) patients with device assisted therapies17
Editorial Board17
The distinctive functional connectivity of the cholinergic nucleus basalis of Meynert in Parkinson’s disease across different cognitive status17
The MemTrax memory test for detecting and assessing cognitive impairment in Parkinson's disease17
¿It Is Any Difference Between Directional Vs Omnidirectional Lead For Treatment In Parkinson Disease?17
Genetic study of early-onset Parkinson's disease in the Malaysian population16
Cognitive and neuropathological contributions to gait dysfunction in Parkinson's disease16
Personality assessment with Temperament and Character Inventory in Parkinson's disease16
Atypical antipsychotic use and mortality risk in Parkinson disease16
Editorial Board16
Frequency settings of subthalamic nucleus DBS for Parkinson's disease: A systematic review and network meta-analysis16
Segmental dystonia as the prominent phenotype resulting from a MICU1 splice variant in a new Indian case16
The impact of anti-inflammatory therapy on Parkinson's disease incidence: A retrospective cohort study15
Gerstmann-Straussler-Scheinker disease: Lessons from two new Indian kindreds15
Single-dose intranasal administration of α-syn PFFs induce lewy neurite-like pathology in olfactory bulbs15
Proteomic profile of saliva in patients with Parkinson's disease after the practice of interval exercise15
Differences in progressive supranuclear palsy in patients of Asian ancestry?15
Diagnostic performance of T1-Weighted MRI gray matter biomarkers in Parkinson's disease: A systematic review and meta-analysis15
MRI index of glymphatic system mediates the influence of locus coeruleus on cognition in Parkinson's disease15
Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis15
Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy15
Motor and non-motor responses of STN DBS in early onset PLA2G6 related Parkinsonism with compound heterozygous mutation from China15
Augmented reality cueing for freezing of gait: Reviewing an emerging therapy15
Levodopa, homocysteine and Parkinson's disease: What's the problem?15
Tardive dyskinesia versus tardive syndrome. What is in a name?15
Phenotypic manifestations of KIF5A Arg1007Lys mutation: A large kindred study14
The factors for choosing intesticular gel therapy14
REM density in Parkinson’s disease: Effects of motor, cognitive, and autonomic function, and the impact of evening dopaminergic medication14
Patients with progressive supranuclear palsy need to be seen sooner and more frequently14
Association between global cognitive function and autonomic dysfunction in patients with de novo Parkinson’s disease14
Interaction between caffeine intake and polymorphisms of PARK16 modifies Parkinson’s Disease risk14
Introducing Virtual Shared Medical Appointments as a Novel Treatment Platform for Functional Movement Disorders14
Neuropsychological studies in children with tic hyperkinesis14
Dopaminergic connectivity reconfiguration in the dementia with Lewy bodies continuum14
Ethnoracial differences for caregiving burden in Parkinson’s disease14
Identification of the needs of patients with Parkinson’s disease through a qualitative research process14
Improvement of non-motor symptoms with NE3107 adjunctive to Carbidopa / Levodopa in patients with Parkinson`s disease: A Phase 2A, placebo-controlled study14
Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) Presenting With Parkinsonism Findings: A Case Report14
ERCC4 variants causing neurodegeneration with ataxia and chorea in three siblings in Lithuanian family14
The feasibility of using loss of “swallow tail sign” on 3T – susceptibility weighted MRI in diagnosis of Parkinson’s disease14
Correcting vertical perception to reverse Pisa syndrome in Parkinson's disease: A case report14
The role of semispinalis capitis muscles in cervical dystonia with goose-neck posture14
Late-onset parkinsonism in a patient with a novel frameshift THAP1 variant13
“A man with an arched back”: Expert commentary13
Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis13
Cerebellar blood perfusion is a diagnostic, but not a prognostic, marker for parkinsonian-dominant type multiple system atrophy13
Sexual dysfunction in patients with focal dystonia13
Analysis of GIPC1 CGG repeat expansions in essential tremor13
Real-world effect of age on long-term effectiveness and safety of levodopa-carbidopa intestinal gel: post hoc analysis from the DUOGLOBE study13
Editorial Board13
Spinocerebellar ataxia subtype 40: Report of a case and review of literature13
Cropland associated with risk of Parkinson's disease in the northern Great Plains13
Motor band sign in a Huntington disease phenocopy13
The effects of once-daily opicapone 50 mg on the pharmacokinetics of levodopa administered as carbidopa/levodopa extended-release capsules: an open-label study13
Empowering the management of early-onset Parkinson’s disease: The role of technology13
Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions13
Seronegative basal ganglia encephalitis mimicking dementia of Lewy body13
Expanding the genotype-phenotype landscape of PDE10A-associated movement disorders12
Reply to: Transcriptomic analysis of plasma small extracellular vesicles identifies potential diagnostic biomarkers for Parkinson's disease dementia12
Comment on “Defining ‘OFF’ time in device-aided therapy criteria for Parkinson's disease: Gaps and opportunities”12
Parkinson's disease with and without history of Agent Orange exposure: A prospective study of US Veterans12
Grey matter correlates of dystonic soft signs in essential tremor12
Reliability of remote video ratings of the scale for assessment and rating of ataxia12
Telomeres, REM sleep, and RBD: A link to neurodegeneration?12
Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study12
Altered subthalamic alpha-beta oscillations in PRKN-associated early onset Parkinson's disease in relation to off-dystonia12
Association between cognitive adverse effects of anticholinergic medication and development of dementia in Parkinson's disease12
Thyroid disease in cervical dystonia12
Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease12
Comparative pharmacokinetics of levodopa–carbidopa intestinal gel infusion and foslevodopa–foscarbidopa continuous subcutaneous infusion therapies in advanced Parkinson's disease12
Tremor is associated with familial clustering of dystonia12
Development of a screening AI model for Parkinson's disease using gait image sequences11
A structural perspective on the interaction between glucocerebrosidase and the positive allosteric modulator BIA 28-615611
Transcranial high-intensity Magnetic Resonance-guided focused ultrasound (tcMRgFUS) – safety and impacts on tremor severity and quality of life11
Response to levodopa in Parkinson's disease over time. A 4-year follow-up study11
The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials11
Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline11
TorsinA-interacting protein 2 (TOR1AIP2) variants in an autosomal dominant combined dystonia-hemichorea-hemiballismus syndrome in two families11
Usage of modern technologies like VR therapy, physio therapy along with levodopa in Young-Onset Parkinson's disease patients11
WITHDRAWN11
Fecal tyrosine decarboxylase and motor response complications in Parkinson's disease11
Post-COVID parkinsonism: A scoping review11
Cognitive function, psychobehavioral symptoms, and MRI features in patients with non-demented Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies11
Recent advances in non-Huntington's disease choreas11
Accelerometric quantification of MDS-UPDRS bradykinesia measurements in PD patients: A pilot study11
Right to the Point - A Writer’s Cramp Successful Treatment11
Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study11
Increased blood-derived mitochondrial DNA copy number in African ancestry individuals with Parkinson's disease11
Magnetic Resonance Imaging Marker for the Conversion from Idiopathic Late-onset Cerebellar Ataxia to Multiple System Atrophy11
Infrathalamic ablation in advanced Parkinson's disease: Three-year outcomes support a safe and accessible therapeutic strategy11
Tongue strength in progressive supranuclear palsy11
Comparison of tetrabenazine, tiapride and olanzapine in Huntington's disease: a one-year French randomized multicenter study (Neuro-HD)11
MRgFUS of the nucleus ventralis intermedius in essential tremor modulates functional connectivity within the classical tremor network and beyond11
Convergence insufficiency and Parkinson's disease progression11
Enhanced low beta activity in Park2-associated Parkinson’s disease10
Utility of clinical tests for asymmetry in Parkinson's disease and Atypical Parkinsonian disorders: the PARK-SYMM scale study.10
Assessment of Cerebral Cortical Atrophy Using Visual Rating Scale in Patients with Functional Movement Disorder10
TMS-evoked potentials provide novel neurophysiological features of Tourette syndrome10
Symptom changes with hormonal variations in genetic dystonia10
Retinal structural changes in Parkinson's disease: differences in pRNFL thickness between GBA1-associated and idiopathic cases10
Editorial Board10
An atypical case of head tremor10
A challenging case of cerebellar ataxia associated with oro facial dominant chorea10
A Novel Missense Mutation in the Spectrin Repeat of SPTBN2 Identified in Spinocerebellar Ataxia Type 510
Developing a Female-Specific Mouse Model for Parkinson’s Disease Using a High-Sensitivity Neural Network10
Influence of Toxic Exposure on the Age of Onset of Parkinson's Disease: An Observational and Analytical Study.10
Analysis of interleukin-6 levels in patients with Parkinson's disease by disease stage10
MOBP gene risk variant is associated with higher cerebrospinal fluid levels of neurofilament light chain: a Barcelona PSP Registry study10
Profile of patients with advanced Parkinson’s disease treated with Levodopa–entacapone–carbidopa intestinal gel (LECIG)10
The use of botulinum toxin A in the treatment of hand tremor10
The influence of fatigue on motor imagery ability in people with Parkinson’s disease – preliminary study10
The iNPH Radscale May Better Predict Whether Ventriculoperitonal Shunting was Offered, Compared to Drain Trial Gait Variables10
Exploring Novel Therapeutic Approaches in Parkinson’s Disease: A Comprehensive Review10
Demonstration of a Prototype Clinical Decision Support System for Diagnosing Parkinson’s Disease10
A benign course of Parkinson's disease associated with different mutations in the glucocerebrosidase gene – A case series10
Calcium channel blockers and Parkinson's disease: A systematic review and meta-analysis10
Challenges during prayer (namaz/salah) rituals in Muslim patients with Parkinson’s disease10
High preoperative gait variability is a prognostic predictor of gait and balance in Parkinson disease patients with deep brain stimulation9
Real world evidence of efficacy ad safety of subcutaneus foslevodopa/foscarbidopa infusion in advanced Parkinson disease9
Structural and functional connectomics of the olfactory system in Parkinson's disease: a systematic review9
Structural and functional brain abnormalities in idiopathic cervical dystonia: a multimodal meta-analysis9
Exploring regional BOLD fluctuations to understand the pathophysiology of mild cognitive impairments in individuals with Parkinson's disease9
Functional movement disorder comorbidity in Parkinson's disease: A multicenter descriptive study9
Resting-state EEG predicts cognitive decline in a neuropathologically diagnosed longitudinal community autopsied cohort9
Preliminary verification of a Kinect-based system for evaluating postural abnormalities in patients with Parkinson’s disease9
Long-term safety of continuous levodopa/carbidopa infusion with ND0612: results from the ongoing BeyoND study9
Diagnosis across a cohort of “atypical” atypical and complex parkinsonism9
A multidisciplinary telemedicine approach for managing frailty in Parkinson's disease. A longitudinal, case-control study9
A novel GNAL pathogenic variant leading to generalized dystonia: Immediate and sustained response to globus pallidus internus deep brain stimulation9
Clinical progression of vascular Parkinsonism in ischemic stroke patients with metabolic syndrome9
Development of osteomyelitis after COVID 19 in patients with vascular parkinsonism9
Comparison of voice parameters, self-assessment of speech and sialorrhea levels in Parkinson's disease patients with and without swallowing problems9
Chorea-acanthocytosis with homozygous variant of VPS13A gene concomitant with intermediate expansion of JPH3 gene: Who is the villain?9
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease9
Real-world local field potential recordings in patients with deep brain stimulation for Parkinson's disease9
Inter-muscular coherence in speed skaters with skater's cramp9
Editorial Board9
Are we ready for automated deep brain stimulation programming?9
Safety and efficacy of VMAT2 inhibitors in Huntington Disease: A systematic review9
Efficacy of Probiotics for treatment of constipation in Parkinson’s patients: a systematic review and meta-analysis9
Double blind, nonrandomized crossover study of active recharge biphasic deep brain stimulation for primary dystonia9
Leucine-rich repeat kinase2 (LRRK2) associated Parkinson's disease: less vulnerable during Covid-19 pandemic?9
Non-pharmacological rehabilitation for people living with advanced Parkinson's disease: A scoping review of interventions9
Association of subthalamic beta frequency sub-bands to symptom severity in patients with Parkinson's disease: A systematic review9
Add-on therapies to levodopa improve pain modulation in Parkinson's disease with motor fluctuations: A prospective cohort study9
A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis9
Backward leaning during gait: An underrecognized sign in Niemann-Pick type C9
Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease9
Progressive Encephalomyelitis with Rigidity and Myoclonus In a Varicella Encephalitis Patient with Primary Meige syndrome8
0.18238091468811